Effects of Aspirin on Colorectal Tumor Prevention

Introduction to Adenomas and Colorectal Cancer

The presence of adenomas, which are benign tumors in the colon, requires immediate medical evaluation, as they can lead to colorectal cancer. Individuals with a prior history of colorectal cancer or adenomas are particularly susceptible to developing new adenomas. While several small studies have indicated that aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) may help prevent future adenomas, the lack of conclusive evidence has stemmed from the small sample sizes and limited number of trials conducted.

Systematic Review by Malaysian Researchers

In an effort to clarify the role of aspirin and NSAIDs in preventing colorectal adenomas, researchers from the International Medical University of Malaysia conducted a systematic review of randomized controlled trials and post-trial reports. The study focused on adult patients with a history of colorectal cancer or adenomas, tracking them for a minimum of one year. The primary objective was to evaluate the effects of aspirin or NSAIDs, regardless of dosage, in preventing colorectal adenomas in this high-risk population. The findings were recently published in BMC Cancer.

Low-Dose Aspirin and Recurrent Tumor Risk

Impact of Aspirin on Adenoma Development

The cumulative data from the study suggest that any dose of aspirin taken for two to four years may lower the risk of developing recurrent adenomas. Given the potential cardiovascular and gastrointestinal side effects associated with higher doses of aspirin, researchers categorized the data based on dosage. Low-dose aspirin demonstrated a statistically significant reduction in the risk of recurrent adenomas. In contrast, higher doses yielded a non-significant reduction in adenoma risk but a significant decrease in recurrent advanced carcinomas.

NSAIDs and Their Efficacy

The systematic review also indicated that other NSAIDs resulted in statistically significant reductions in the risk of developing both recurrent and advanced adenomas over a three-year follow-up period. However, the adverse effects associated with COX-2 inhibitors—a subset of NSAIDs—limit their viability as protective agents against colorectal cancer.

Limitations and Future Research Directions

Duration of Treatment and Its Implications

A critical aspect of evaluating the beneficial effects of aspirin and NSAIDs on recurrent adenomas is the duration of treatment. The researchers examined four post-trial reports to assess whether the protective effects persist after discontinuation of the drugs. Due to limitations in study size, number of trials, and follow-up duration, no definitive conclusions could be made regarding the loss of efficacy following drug withdrawal.

Conclusions and Recommendations

The findings suggest that aspirin and NSAIDs may offer protective benefits against recurrent adenomas for patients with a history of colorectal cancer or adenomas, with aspirin showing a more favorable side effect profile. Nonetheless, further studies are necessary to ascertain the risk of recurrence after stopping drug therapy. Given the apparent safety and efficacy of low-dose aspirin in preventing colorectal adenomas, high-quality randomized controlled trials are essential to confirm its role in reducing the risk of adenoma recurrence.

Written by Jessica Caporuscio, PharmD

Reference

Veettil SK, Lim KG, Ching SM, et al. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMC Cancer. 2017.